Still SF [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2016-10-06 22:13 (2141 d 23:08 ago) – Posting: # 16702
Views: 11,930

Hello VStus,

» But back to reality: isn't it more practical in case of HVD to perform pilot on development with let's say 50% power (wondering: replicated pilot to keep reasonable small population?), better understand in-vitro in-vivo relationship, optimize formulation and than run replicate scaled trial? In 2-stage we also need to wait for results from the 1st stage...

Yes
Nitpicking: you perform a 2-stage trial or a pilot trial because you do not know the variability, right? Which means the "let's say 50% power" in actuality means guessworking. Optimizing the formulation on basis of a pilot trial with inherently low power (=high uncertainty on the PE) is in scientific terms as solid as tarot cards or crystal healing.
I read on LinkedIn the other day: "The flat earth society has members all over the globe" :-D:-D:-D

OK, surely I will get in trouble for this post.
:pirate:

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 15 (0 registered, 15 guests [including 9 identified bots]).
Forum time: Thursday 21:21 CEST (Europe/Vienna)

On two occasions I have been asked,—“Pray, Mr. Babbage,
if you put into the machine wrong figures,…
will the right answers come out?”
 …
I am not able rightly to apprehend the kind of confusion of ideas
that could provoke such a question.    Charles Babbage

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5